Sorafenib is effective in the treatment of pulmonary veno-occlusive disease.

Abstract

The present study is the first report of the effectiveness of sorafenib in the treatment of pulmonary veno-occlusive disease (PVOD). A 66-year-old woman with PVOD was started on sorafenib. After 3 months of treatment with a maximum dosage of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart Association (NYHA) functional class from IV to III. However, because of severe painful eruptions as a side effect of sorafenib, the patient stopped sorafenib and was started on imatinib instead. This treatment resulted in a worsening of the patient's NYHA class from III to IV, so sorafenib was restarted at a reduced dosage of 300 mg/day. The resumption of sorafenib was associated with clinical improvement, specifically NYHA class from IV to II and hemodynamic amelioration, and tolerable eruptions. In conclusion, sorafenib may be a potential therapeutic strategy for the treatment of PVOD.

• Authors: Masaharu Kataoka, Ryoji Yanagisawa, Keiichi Fukuda, Hideaki Yoshino, Toru Satoh
• Journal: Cardiology (Cardiology) Vol. 123 Issue 3 Pg. 172-4 ( 2012) ISSN: 1421-9751 [Electronic] Switzerland
• PMID: 23128832 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2012 S. Karger AG, Basel.

Chemical References

• Benzamides
• Phenylurea Compounds
• Piperazines
• Protein Kinase Inhibitors
• Pyrimidines
• Niacinamide
• Imatinib Mesylate
• Sorafenib

Topics

• Aged
• Benzamides (therapeutic use)
• Drug Therapy, Combination
• Female
• Hemodynamics (drug effects)
• Humans
• Imatinib Mesylate
• Niacinamide (analogs & derivatives, therapeutic use)
• Phenylurea Compounds (therapeutic use)
• Piperazines (therapeutic use)
• Protein Kinase Inhibitors (therapeutic use)
• Pulmonary Veno-Occlusive Disease (drug therapy)
• Pyrimidines (therapeutic use)
• Sorafenib
• Treatment Outcome